Still another moderate year ahead
25/02/21 -"Bayer really needs a kind of breakthrough or a brilliant idea to change the sentiment on the name. We understand glyphosate-related issues and the related payments continue to weigh on CF, but the ..."
Pages
78
Language
English
Published on
25/02/21
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...